Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Dr. Reddy\'s Laboratories

              • Development Update

              Virtual BoothOffering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

              INDIA India

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              DCAT Week 2021

              Attending

              Request a Meeting Now

              Dr. Reddy’s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overa...

              Contact the Supplier

              Lead Product(s): Denileukin Diftitox,Anti-PD-1 agent

              Therapeutic Area: Oncology Product Name: E7777

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Eisai

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 09, 2020

              Details:

              Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.

              Aurigene

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              INDIA India

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              Exelixis In-Licenses Aurigene’s CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Trial in Advanced Solid Tumors

              Contact the Supplier

              Lead Product(s): XL102

              Therapeutic Area: Oncology Product Name: XL102

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Exelixis

              Deal Size: $29.5 million Upfront Cash: $10.0 million

              Deal Type: Licensing Agreement December 07, 2020

              Details:

              Exelixis has exercised exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the compound now known as XL102.

              PharmaCompass__DigitalAd